+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Netupitant-Palonosetron FDC Global Market Report 2025

  • PDF Icon

    Report

  • 175 Pages
  • July 2025
  • Region: Global
  • The Business Research Company
  • ID: 6104973
The netupitant-palonosetron fixed dose combination (FDC) market size has grown strongly in recent years. It will grow from $351.5 billion in 2024 to $384.5 billion in 2025 at a compound annual growth rate (CAGR) of 9.5%. Growth during the historic period was driven by the rising adoption of combination antiemetic therapies, greater awareness among oncologists, a growing number of cancer cases, increasing clinical evidence of safety and efficacy, and improved access to cancer treatment in emerging markets.

The netupitant-palonosetron fixed dose combination (FDC) market size is expected to see strong growth in the next few years. It will grow to $555.45 billion in 2029 at a compound annual growth rate (CAGR) of 9.6%. Key factors contributing to this growth include increased focus on enhancing quality of life during chemotherapy, the rising trend of home-based chemotherapy treatment, demand for user-friendly antiemetic regimens, and the preference for oral fixed-dose combinations over multiple separate medications. Notable trends in the forecast period include advances in therapeutic options, development of dual-action formulations, innovations in technology-driven drug formulation, creation of oral-disintegrating dosage forms, and improved control of multiday emesis.

The increasing prevalence of cancer is expected to propel the growth of the netupitant-palonosetron fixed-dose combination (FDC) market going forward. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The increasing prevalence of cancer is due to lifestyle choices such as poor diet, smoking, physical inactivity, and excessive alcohol consumption. Netupitant-palonosetron fixed-dose combination (FDC) enhances cancer treatment by combining two effective antiemetic agents, preventing both acute and delayed chemotherapy-induced nausea and vomiting. They improve patient comfort and adherence to treatment, supporting better overall care outcomes. For instance, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, the number of cancer cases diagnosed in Australia reached 160,570 in 2022, marking an increase of 3,789 cases from 156,781 in 2021. Therefore, the increasing prevalence of cancer is driving the growth of the netupitant-palonosetron fixed-dose combination (FDC) market.

The rising demand for oral drugs is expected to propel the growth of the netupitant-palonosetron fixed-dose combination (FDC) market going forward. Oral drugs refer to medications that are taken by mouth and absorbed through the digestive system to treat or prevent various health conditions. The rising demand for oral drugs is due to their convenience and ease of administration, allowing patients to self-administer medication without the need for professional assistance. Netupitant-palonosetron FDC enhances the effectiveness of oral drugs by preventing nausea and vomiting, thereby improving patient compliance and treatment outcomes. For instance, in October 2022, according to the Centers for Disease Control and Prevention, a US-based government administration, the dispensing of oral antivirals rose by 57%, increasing from 643 per 100,000 persons between April 24 and May 21, 2022, to 1,012 per 100,000 persons between July 31 and August 28, 2022. Therefore, the rising demand for oral drugs drives the growth of the netupitant-palonosetron fixed-dose combination (FDC) market.

Major companies operating in the netupitant-palonosetron fixed-dose combination (FDC) market are focusing on developing advanced formulation products, such as ready-to-use intravenous formulations, to enhance patient convenience and treatment efficacy. Ready-to-use intravenous formulations are pre-prepared, sterile drug solutions that eliminate the need for dilution or mixing, helping netupitant-palonosetron fixed-dose combination (FDC) by simplifying administration and reducing preparation errors. For instance, in June 2024, Helsinn Group, a Switzerland-based pharmaceutical company, launched AKYNZEO (fosnetupitant/palonosetron) injection, a ready-to-use vial made available in the United States. This new formulation is designed to simplify preparation and administration for healthcare providers, enhancing convenience in clinical settings. The injection requires no reconstitution or dilution and can be infused directly from the vial using an integrated hanging strap.

Major players in the netupitant-palonosetron fixed dose combination (fdc) market are Taiho PharmaceuticalTaiho Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd, Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Zhejiang Tiantai Pharmaceutical Co. Ltd., Hikma Pharmaceuticals PLC, Glenmark Pharmaceuticals Limited, Helsinn Group, Heron Therapeutics Inc., Metrochem API Private Limited, Mundipharma Pty Ltd, Guangzhou Tosun Pharmaceutical Co. Ltd., Tesaro Inc., Accord Healthcare Ltd., Century Pharmaceuticals Ltd., Specialised Therapeutics Australia Pty Ltd., Aark Pharmaceuticals Ltd., Chemicea Pharmaceuticals Pvt. Ltd., Teva Pharmaceutical Industries Ltd.

North America was the largest region in the netupitant-palonosetron fixed dose combination (FDC) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in netupitant-palonosetron fixed dose combination (FDC) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the netupitant-palonosetron fixed dose combination (FDC) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The netupitant-palonosetron fixed-dose combination (FDC) is a pharmaceutical formulation that integrates two active ingredients - netupitant, a neurokinin-1 (NK1) receptor antagonist, and palonosetron, a serotonin (5-HT3) receptor antagonist - into a single dose. This combination is mainly used to prevent both acute and delayed nausea and vomiting associated with chemotherapy. Netupitant functions by blocking the action of substance P at NK1 receptors in the brain, while palonosetron inhibits serotonin activity at 5-HT3 receptors, which are central to the development of chemotherapy-induced nausea and vomiting (CINV).

The primary product types in the netupitant-palonosetron fixed-dose combination (FDC) market include netupitant, palonosetron, and the fixed-dose combination (FDC) itself. Netupitant is used to prevent chemotherapy-induced nausea and vomiting by targeting substance P/neurokinin 1 (NK1) receptors. It is administered via oral, intravenous (IV), and sublingual routes, and is used in the management of chemotherapy-induced nausea and vomiting (CINV), postoperative nausea and vomiting (PONV), and general nausea. Distribution channels include hospitals, retail pharmacies, online pharmacies, and specialty clinics.

The netupitant-palonosetron fixed dose combination (FDC) market research report is one of a series of new reports that cover netupitant-palonosetron fixed dose combination (FDC) market statistics, including the netupitant-palonosetron fixed dose combination (FDC) industry's global market size, regional shares, competitors with the netupitant-palonosetron fixed dose combination (FDC) market share, detailed netupitant-palonosetron fixed dose combination (FDC) market segments, market trends and opportunities, and any further data you may need to thrive in the netupitant-palonosetron fixed dose combination (FDC) market. This netupitant-palonosetron fixed dose combination (FDC) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The netupitant-palonosetron fixed dose combination (FDC) market consists of sales of oral capsules, injectable formulations, premixed infusion bags, combination therapy kits, and generic versions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.

Table of Contents

1. Executive Summary2. Netupitant-Palonosetron Fixed Dose Combination (FDC) Market Characteristics3. Netupitant-Palonosetron Fixed Dose Combination (FDC) Market Trends And Strategies4. Netupitant-Palonosetron Fixed Dose Combination (FDC) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Netupitant-Palonosetron Fixed Dose Combination (FDC) Growth Analysis And Strategic Analysis Framework
5.1. Global Netupitant-Palonosetron Fixed Dose Combination (FDC) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Netupitant-Palonosetron Fixed Dose Combination (FDC) Market Growth Rate Analysis
5.4. Global Netupitant-Palonosetron Fixed Dose Combination (FDC) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Netupitant-Palonosetron Fixed Dose Combination (FDC) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Netupitant-Palonosetron Fixed Dose Combination (FDC) Total Addressable Market (TAM)
6. Netupitant-Palonosetron Fixed Dose Combination (FDC) Market Segmentation
6.1. Global Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Netupitant
  • Palonosetron
  • Fixed Dose Combination (FDC)
6.2. Global Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oral Administration
  • Intravenous (IV) Administration
  • Sublingual Administration
6.3. Global Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Chemotherapy Induced Nausea And Vomiting (CINV)
  • Postoperative Nausea And Vomiting (PONV)
  • General Nausea Management
6.4. Global Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Retail Pharmacies
  • Online Pharmacies
  • Specialty Clinics
6.5. Global Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Sub-Segmentation Of Netupitant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oral Netupitant
  • Injectable Netupitant
6.6. Global Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Sub-Segmentation Of Palonosetron, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oral Palonosetron
  • Injectable Palonosetron
6.7. Global Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Sub-Segmentation Of Fixed Dose Combination, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oral Fixed Dose Combination
  • Intravenou Fixed Dose Combination
7. Netupitant-Palonosetron Fixed Dose Combination (FDC) Market Regional And Country Analysis
7.1. Global Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Netupitant-Palonosetron Fixed Dose Combination (FDC) Market
8.1. Asia-Pacific Netupitant-Palonosetron Fixed Dose Combination (FDC) Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Netupitant-Palonosetron Fixed Dose Combination (FDC) Market
9.1. China Netupitant-Palonosetron Fixed Dose Combination (FDC) Market Overview
9.2. China Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Netupitant-Palonosetron Fixed Dose Combination (FDC) Market
10.1. India Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Netupitant-Palonosetron Fixed Dose Combination (FDC) Market
11.1. Japan Netupitant-Palonosetron Fixed Dose Combination (FDC) Market Overview
11.2. Japan Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Netupitant-Palonosetron Fixed Dose Combination (FDC) Market
12.1. Australia Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Netupitant-Palonosetron Fixed Dose Combination (FDC) Market
13.1. Indonesia Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Netupitant-Palonosetron Fixed Dose Combination (FDC) Market
14.1. South Korea Netupitant-Palonosetron Fixed Dose Combination (FDC) Market Overview
14.2. South Korea Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Netupitant-Palonosetron Fixed Dose Combination (FDC) Market
15.1. Western Europe Netupitant-Palonosetron Fixed Dose Combination (FDC) Market Overview
15.2. Western Europe Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Netupitant-Palonosetron Fixed Dose Combination (FDC) Market
16.1. UK Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Netupitant-Palonosetron Fixed Dose Combination (FDC) Market
17.1. Germany Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Netupitant-Palonosetron Fixed Dose Combination (FDC) Market
18.1. France Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Netupitant-Palonosetron Fixed Dose Combination (FDC) Market
19.1. Italy Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Netupitant-Palonosetron Fixed Dose Combination (FDC) Market
20.1. Spain Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Netupitant-Palonosetron Fixed Dose Combination (FDC) Market
21.1. Eastern Europe Netupitant-Palonosetron Fixed Dose Combination (FDC) Market Overview
21.2. Eastern Europe Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Netupitant-Palonosetron Fixed Dose Combination (FDC) Market
22.1. Russia Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Netupitant-Palonosetron Fixed Dose Combination (FDC) Market
23.1. North America Netupitant-Palonosetron Fixed Dose Combination (FDC) Market Overview
23.2. North America Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Netupitant-Palonosetron Fixed Dose Combination (FDC) Market
24.1. USA Netupitant-Palonosetron Fixed Dose Combination (FDC) Market Overview
24.2. USA Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Netupitant-Palonosetron Fixed Dose Combination (FDC) Market
25.1. Canada Netupitant-Palonosetron Fixed Dose Combination (FDC) Market Overview
25.2. Canada Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Netupitant-Palonosetron Fixed Dose Combination (FDC) Market
26.1. South America Netupitant-Palonosetron Fixed Dose Combination (FDC) Market Overview
26.2. South America Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Netupitant-Palonosetron Fixed Dose Combination (FDC) Market
27.1. Brazil Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Netupitant-Palonosetron Fixed Dose Combination (FDC) Market
28.1. Middle East Netupitant-Palonosetron Fixed Dose Combination (FDC) Market Overview
28.2. Middle East Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Netupitant-Palonosetron Fixed Dose Combination (FDC) Market
29.1. Africa Netupitant-Palonosetron Fixed Dose Combination (FDC) Market Overview
29.2. Africa Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Netupitant-Palonosetron Fixed Dose Combination (FDC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Netupitant-Palonosetron Fixed Dose Combination (FDC) Market Competitive Landscape And Company Profiles
30.1. Netupitant-Palonosetron Fixed Dose Combination (FDC) Market Competitive Landscape
30.2. Netupitant-Palonosetron Fixed Dose Combination (FDC) Market Company Profiles
30.2.1. Taiho PharmaceuticalTaiho Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Chugai Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Eisai Co. Ltd Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Dr. Reddy’s Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Aurobindo Pharma Limited Overview, Products and Services, Strategy and Financial Analysis
31. Netupitant-Palonosetron Fixed Dose Combination (FDC) Market Other Major And Innovative Companies
31.1. Zhejiang Tiantai Pharmaceutical Co. Ltd.
31.2. Hikma Pharmaceuticals PLC
31.3. Glenmark Pharmaceuticals Limited
31.4. Helsinn Group
31.5. Heron Therapeutics Inc.
31.6. Metrochem API Private Limited
31.7. Mundipharma Pty Ltd
31.8. Guangzhou Tosun Pharmaceutical Co. Ltd.
31.9. Tesaro Inc.
31.10. Accord Healthcare Ltd.
31.11. Century Pharmaceuticals Ltd.
31.12. Specialised Therapeutics Australia Pty Ltd.
31.13. Aark Pharmaceuticals Ltd.
31.14. Chemicea Pharmaceuticals Pvt. Ltd.
31.15. Teva Pharmaceutical Industries Ltd.
32. Global Netupitant-Palonosetron Fixed Dose Combination (FDC) Market Competitive Benchmarking And Dashboard33. Key Mergers And Acquisitions In The Netupitant-Palonosetron Fixed Dose Combination (FDC) Market34. Recent Developments In The Netupitant-Palonosetron Fixed Dose Combination (FDC) Market
35. Netupitant-Palonosetron Fixed Dose Combination (FDC) Market High Potential Countries, Segments and Strategies
35.1 Netupitant-Palonosetron Fixed Dose Combination (FDC) Market In 2029 - Countries Offering Most New Opportunities
35.2 Netupitant-Palonosetron Fixed Dose Combination (FDC) Market In 2029 - Segments Offering Most New Opportunities
35.3 Netupitant-Palonosetron Fixed Dose Combination (FDC) Market In 2029 - Growth Strategies
35.3.1 Market Trend Based Strategies
35.3.2 Competitor Strategies
36. Appendix
36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. About the Analyst
36.6. Copyright And Disclaimer

Executive Summary

Netupitant-Palonosetron FDC Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on netupitant-palonosetron fdc market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase:

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Description

Where is the largest and fastest growing market for netupitant-palonosetron fdc ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The netupitant-palonosetron fdc market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:
  • The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Product Type: Netupitant; Palonosetron; Fixed Dose Combination (FDC)
2) By Route Of Administration: Oral Administration; Intravenous (IV) Administration; Sublingual Administration
3) By Application: Chemotherapy Induced Nausea And Vomiting (CINV); Postoperative Nausea And Vomiting (PONV); General Nausea Management
4) By Distribution Channel: Hospitals; Retail Pharmacies; Online Pharmacies; Specialty Clinics

Subsegments:

1) By Netupitant: Oral Netupitant; Injectable Netupitant
2) By Palonosetron: Oral Palonosetron; Injectable Palonosetron
3) By Fixed Dose Combination: Oral Fixed Dose Combination; Intravenou Fixed Dose Combination

Key Companies Profiled: Taiho PharmaceuticalTaiho Pharmaceutical Co. Ltd.; Chugai Pharmaceutical Co. Ltd.; Eisai Co. Ltd; Dr. Reddy’s Laboratories Ltd.; Aurobindo Pharma Limited

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery Format: PDF, Word and Excel Data Dashboard.

Companies Mentioned

  • Taiho PharmaceuticalTaiho Pharmaceutical Co. Ltd.
  • Chugai Pharmaceutical Co. Ltd.
  • Eisai Co. Ltd
  • Dr. Reddy’s Laboratories Ltd.
  • Aurobindo Pharma Limited
  • Zhejiang Tiantai Pharmaceutical Co. Ltd.
  • Hikma Pharmaceuticals PLC
  • Glenmark Pharmaceuticals Limited
  • Helsinn Group
  • Heron Therapeutics Inc.
  • Metrochem API Private Limited
  • Mundipharma Pty Ltd
  • Guangzhou Tosun Pharmaceutical Co. Ltd.
  • Tesaro Inc.
  • Accord Healthcare Ltd.
  • Century Pharmaceuticals Ltd.
  • Specialised Therapeutics Australia Pty Ltd.
  • Aark Pharmaceuticals Ltd.
  • Chemicea Pharmaceuticals Pvt. Ltd.
  • Teva Pharmaceutical Industries Ltd.